Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

The present study aimed to determine the safety and activity of the histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia (WM). Eligibility criteria included patients with relapsed/refractory WM with any number of prior therapies. Patients rece...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Ghobrial, Irene M., Campigotto, Federico, Murphy, Timothy J., Boswell, Erica N., Banwait, Ranjit, Azab, Feda, Chuma, Stacey, Kunsman, Janet, Donovan, Amanda, Masood, Farzana, Warren, Diane, Rodig, Scott, Anderson, Kenneth C., Richardson, Paul G., Weller, Edie, Matous, Jeffrey
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2013
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3578951/
https://ncbi.nlm.nih.gov/pubmed/23287861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-06-439307
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items